Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Guselkumab (Primary) ; Secukinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Dec 2018 Results presented in the Janssen Pharmaceuticals media release.
    • 12 Dec 2018 Primary endpoint has been met. (Percentage of Participants who Achieve Psoriasis Area and Severity Index (PASI) 90 Response at Week 48), as reported in a MorphoSys Media Release
    • 12 Dec 2018 Results published in the MorphoSys Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top